Abstract
The purpose of this study is visual evaluation of the distribution of I-123 iomazenil in the brains of patients with various types of mental disorder and to examine whether chronic administration of a clinical dose of benzodiazepine (BZ) affects the binding of I-123 iomazenil to BZ receptors (BZR). The subjects were 10 patients with mental disorders (3 males and 7 females) with a mean age of 26.8 yrs (range 19–39 yrs). Four of 10 patients were administered BZ for over 3 months and the other six were free of BZ for over one month. The SPECT images were obtained at 5–25 min (early) and 170–190 min (delayed), after the bolus i.v. injection of 167 MBq of I-123 iomazenil, with a triplehead gamma camera. The images were visually evaluated and the washout ratios of each region were calculated. In visual analysis, abnormalities were recognized in 5 patients on the delayed SPECT. The abnormalities were recognized more frequently in the superior frontal lobe. The washout ratio was higher in the BZ (+) patient group than in the BZ (−) patient group. I-123 iomazenil is useful, because the SPECT image with I-123 iomazenil reflects the distribution of BZR on the brain and provides the different information from that obtained with perfusion SPECT, X-ray CT or MRI. The rapid washout of I-123 iomazenil from the brains of BZ (+) patients suggests that chronic administration of a clinical dose of BZ affects the binding of I-123 iomazenil to BZR.
This is a preview of subscription content, log in via an institution to check access.
References
Beer HF, Blauenstein PA, Hasler PH, Delaloye B, Riccabona G, Bangerl I, et al.In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors.J Nucl Med 31:1007–1014, 1990.
Innis R, Zoghbi S, Johnson E, Woods S, Al-Tikiriti M, Baldwin R, et al. SPECT imaging of the benzodiazepine receptor in non-human primate brain with [123I]Ro 16-0154.Eur J Pharmacol 193: 249–252, 1991.
Innis RB, Al-Tikiriti MS, Zoghbi S, Baldwin RM, Sybirska EH, Laruelle MA, et al. SPECT imaging of the benzodiazepine receptor: feasibility ofin vivo potency measurements from stepwise displacement curve.J Nucl Med 32: 1754–1761, 1991.
Feistel H, Kaschka WP, Ebert D, Koraschky P, Wolf F. Assessment of cerebral benzodiazepine receptor distribution in anxiety disorders—A study with I-123-IOMAZENIL.J Nucl Med 34: 47, 1993. (abstract)
Uchiyama M, Sue H, Fukumitu N, Mori Y, Kawakami K. Assessment cerebral benzodiazepine receptor distribution in anxiety disorder by123I-iomazenil-SPECT: comparison to cerebral perfusion scintigraphy byI23I-IMP.Nippon Acta Radiol 57: 41–46, 1997. (in Japanese)
Schlegel S, Steinert H, Bockisch A, Hahn K, Schloesser R, Benkert O. Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report.Eur Arch Psychiatry Clin Neurosci244 (1): 49–51, 1944.
Kuikka JT, Pitkanen A, Lepola U, Partanen K, Vainio P, Bergstrom KA, et al. Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. Nucl Med Commun. 16 (4): 273–280, 1995.
Yonekura Y, Nishizawa S, Tanaka F, Ishizu K, Okazawa H, Fujita T, et al. Phase 1 clinical study ofI23I-iomazeniI: a new probe to evaluate central-type benzodiazepine receptor with SPECT.KAKU IGAKU (Jpn J Nucl Med) 32: 87–97, 1995. (in Japanese)
Onishi Y, Yonekura Y, Tanaka F, Nishizawa S, Okazawa H, Ishizu K, et al. Delayed image of iodine-123 ionnazenil as a relative map of benzodiazepine receptor binding: the optimal scan time.Eur J Nucl Med 23: 1491–1497, 1996.
Benson DF.The Neurology of Thinking.1st ed., New York: Oxford University Predss, 1994.
Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders.J Neuropsychiatry Clin Neurosci 6 (4): 358–370, 1994.
Goldman-Rakic PS. Working memory dysfunction in schizophrenia.J Neuropsychiatry Clin Neurosci 6 (4): 348–357, 1994.
Seidman LJ, Yurgelun-Todd D, Kremen WS, Woods BT, Goldstein JM, Faraone SV, et al. Relationship of prefrontal and temporal lobe MRI measures to neuro-psychological performance in chronic schizophrenia.Biol Psychiatry 35 (4): 235–246, 1994.
Sybirska E, Seibyl JP, Bremner JD, Baldwin RM, Al-Tikiriti MS, Bradberry C, et al. [123I]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain.Neuropharmacology 32: 671–680, 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakabeppu, Y., Nakajo, M., Naruo, T. et al. I-123 iomazenil SPECT in patients with mental disorders. Ann Nucl Med 11, 339–344 (1997). https://doi.org/10.1007/BF03165304
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03165304